In the News
Low-dose aspirin may not reduce cardiovascular events in diabetic patients
The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial included 2,539 patients with type 2 diabetes and without pre-existing cardiovascular disease, randomized to receive aspirin (81 mg or 100 mg daily) or no aspirin.
Clinicians should integrate psychosocial components into diabetes care, ADA recommends
The position statement recommends that physicians consider assessing cognitive capacities and symptoms of diabetes distress, depression, anxiety, and disordered eating at the initial visit and at periodic intervals.
No apparent association between glycemic control, outcomes in diabetic nursing home residents
The study included patients 65 years of age and older with type 1 or type 2 diabetes admitted to a Veterans Affairs nursing home, and they were categorized by baseline HbA1c (6.0% to 6.9%, 7.0% to 7.9%, 8.0% to 8.9%, and 9.0% or higher).
MKSAP quiz: Preoperative glycemic control
This month's quiz asks readers to evaluate a 68-year-old man with a right intertrochanteric fracture scheduled for surgical repair. He takes insulin glargine and insulin lispro.
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
New indication approved for empagliflozin
Empagliflozin (Jardiance) is approved for a new indication—to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease.
Spotlight on hospitalized patients with diabetes
Recent studies of hospitalized patients looked at hypoglycemia and mortality, hyperglycemia and sleep, and corticosteroids for pneumonia.